Regulatory T-cells and their impacts on cytokine profile of end-stage renal disease patients suffering from systemic lupus erythematosus

Fathi, Farshid; Atapour, Abdolamir; Eskandari, Nahid; Keyhanmehr, Niloufar; Hafezi, Hossein; Mohammadi, Shohreh; Motedayyen, Hossein

doi:10.1177/2058738419863238

Cited by 17 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, protein-energy malnutrition (PEM), a common and severe complication of CKD, induces T-lymphopenia and T-lymphocyte dysfunction ( 33 ). Several studies indicated that ESKD patients have T-lymphocyte dysfunctions, such as the reduction of regulatory T-cells (Tregs), a subgroup of CD4 + T cells ( 34 , 35 ). Furthermore, because Tregs inhibit systemic inflammation and CVD, deficiency of Tregs might be one reason for some complications in ESRD patients, including CVD ( 36 ).…”

Section: Discussionmentioning

confidence: 99%

T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease

Xiong

Qiao

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: T-lymphocyte subsets reflect patients' immune status and are associated with adverse outcomes in various diseases. However, the association between T-lymphocyte subsets and major infection and renal outcome in chronic kidney disease (CKD) patients has not been well-addressed.Methods: Patients diagnosed with stage 3–5 of non-dialysis CKD were recruited, and healthy subjects were selected as the controls. T-lymphocyte subsets (CD3+, CD4+, CD8+) were detected by flow cytometry, and the CD4+/CD8+ T cell ratio was then calculated. Patients were divided into the normal-level group and the low-level group according to the clinical reference value. The primary outcomes were the major infection and renal outcome.Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. Compared to the healthy controls, the level of CD3+, CD4+, CD8+ T cells, and the CD4+/CD8+ T cell ratio were significantly decreased in CKD patients (p < 0.05). During the median follow-up of 2.56 (quartile interval 1.24–3.46) years, major infections occurred in 15.10% of the CKD patients. The incidence of infection was significantly higher in the low-level group of CD3+, CD4+ T cells, and CD4+/CD8+ T cell ratio compared with the normal level groups. Kaplan-Meier analysis showed that the lower level of CD3+, CD4+ T cells, and CD4+/CD8+T cell ratio is associated with a greater risk of infection. Cox regression analysis further confirmed that low CD3+, CD4+ T cells, and CD4+/CD8+ T cell ratio were independent risk factors of infection in CKD patients. Moreover, during the follow-up, renal events occurred in 37.50% of patients. Kaplan-Meier analysis indicated that low levels of CD3+, CD4+, and CD8+ T cells are significantly associated with renal outcome in CKD patients. Cox regression analysis showed that low level of CD3+ T cells (HR = 2.407, 95% CI: 1.664–3.482, p < 0.001), CD4+ T cells (HR = 2.397, 95% CI: 1.633–3.518, p < 0.001) and CD8+ T cells (HR = 2.416, 95% CI: 1.476–3.955, p < 0.001) were independent risk factors for renal outcome after multivariable-adjusted.Conclusion: CKD patients had a defect in T-lymphocyte subpopulation. T-lymphocyte subsets were closely associated with infection and renal outcome in CKD patients. Suggesting T-lymphocyte subsets are independent predictors of infection and renal outcome in CKD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease

Xiong

Qiao

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…60 These cells have well-known roles in suppressing different cells from the immune system and inhibiting productions of pro-inflammatory cytokines leading to tumor progression via the increment of the tumor cell escape from the immune system and promotion of tumor growth. [61][62][63][64][65][66]…”

Section: Discussionmentioning

confidence: 99%

Changes in immune profile affect disease progression in hepatocellular carcinoma

Fathi

Saidi

Banafshe

et al. 2022

Int J Immunopathol Pharmacol

Self Cite

View full text Add to dashboard Cite

Objective: Hepatocellular carcinoma (HCC) as a chronic liver condition is largely associated with immune responses. Previous studies have revealed that different subsets of lymphocytes play fundamental roles in controlling or improving the development and outcome of solid tumors like HCC. Hence, this study aimed to investigate whether immune system changes were related to disease development in HCC patients. Methods: Peripheral blood mononuclear cells were isolated from 30 HCC patients and 30 healthy volunteers using Ficoll density centrifugation. The isolated cells were stained with different primary antibodies and percentages of different immune cells were determined by flow cytometry. Results: HCC patients indicated significant reductions in the numbers of CD4+ cells, Tbet+IFNγ+cells, and GATA+IL-4+cells in peripheral blood in comparison with healthy individuals ( p < 0.05). There was no significant change in IL-17+RORγt+cells between patient and healthy groups. In contrast, Foxp3+CD127lowcell frequency was significantly higher in patients than healthy subjects ( p < 0.0001). The numbers of Th1, Th2, and Th17 cells were significantly lower in HCC patients than healthy control ( p < 0.0001), although the reduction in Th2 cell numbers was not statistically significant. On the contrary, Treg percentage showed a significant increase in patients compared to healthy subjects ( p < 0.0001). Other data revealed that Th1, Th2, and Th17 cell frequencies were significantly higher in healthy individuals than patients with different TNM stages of HCC, with the exception of Th2 in patients with stage II HCC ( p < 0.01–0.05). Treg percentage was significantly increased in patients with different TNM stages ( p < 0.0001). Among all CD4+ T cells, the frequency of Th2 cell was significantly associated with TNM stages of HCC ( p < 0.05). Conclusion: Our data provide further evidence to show that immune changes may participate in determining HCC progression and disease outcome. However, it should be mentioned that more investigations are needed to clarify our results and explain possible impacts of other immune cells on the pathogenesis of HCC.

show abstract

“…The influence of ESRD or dialysis therapy on the development of BP remains to be elucidated. Although the reduction of regulatory T cells has been reported to affect the predominance of BP in elderly population [ 19 , 20 ], circulating regulatory T cells were not decreased in ESRD patients, compared with healthy subjects [ 31 ]. In addition, circulating regulatory T cell level was independent of glomerular filtration rate and serum levels of urea nitrogen and creatinine [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey

et al. 2021

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease. Although several cases of BP in end-stage renal disease patients receiving peritoneal dialysis (PD) or hemodialysis have been reported, the incidence of BP in these patients remains unknown. We recently experienced three PD patients diagnosed with BP. The skin injury was likely to be a trigger of BP in all the three PD patients. Nifedipine and icodextrin exposures were possible factors directly or indirectly affecting the onset of BP, because they were common in the three cases. We also report that the incidence of BP in PD patients was 3/478.3 person-years in a single-center 10-year study. This case series with a literature survey describes that the skin and tissue injuries are potential triggers responsible for the onset of BP in dialysis patients and that the incidence of BP in these patients seems to be much higher than that in the general population.

show abstract

Regulatory T-cells and their impacts on cytokine profile of end-stage renal disease patients suffering from systemic lupus erythematosus

Cited by 17 publications

References 31 publications

T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease

T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease

Changes in immune profile affect disease progression in hepatocellular carcinoma

Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey

Contact Info

Product

Resources

About